Granules India and Ajinomoto OmniChem create jv in India

Published: 18-Jul-2011
Manufacturing Ingredients Finance Pharmaceutical

Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh

Belgian chemicals company Ajinomoto OmniChem and Indian pharmaceuticals manufacturer Granules India have formed a 50:50 joint venture to produce active pharmaceutical ingredients (APIs) and intermediates for third parties.

The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.

Construction of the facility will start in November and should be completed towards the end of 2012.

The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.

Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.

‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.

Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.

Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.

See more

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

Read more
The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India

Trending Articles

  1. WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Britain's biotech potential (part I): world-class science, second-class support? The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
  5. Freudenberg Medical launches CleanAssure ISO Class 5 cleanroom service for sterile single-use biopharma assemblies CleanAssure is an ISO Class 5 controlled cleanroom service delivering washed, dried and gamma-sterilised single-use assemblies to biopharmaceutical customers, addressing industry challenges around cleaning validation and contamination risk

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India
Finance

Indian Big Pharma companies buck the global economic trend

India\'s top 25 pharma companies continue to go from strength to strength
Finance

BASF reports Q1 earnings as currency headwinds and Middle East conflict weigh on revenue

The German chemicals giant posted solid volume growth across most segments in the first quarter of 2026, but adverse currency effects eroded sales and pushed EBITDA before special items down
Manufacturing

DINAMIQS secures Swissmedic licence for viral vector GMP manufacturing at Zurich facility

Siegfried-owned DINAMIQS has gained Swissmedic approval to manufacture and release ATMPs, establishing itself as Switzerland’s first fully integrated viral vector CDMO with end-to-end cGMP capabilities.
Manufacturing

VIVEbiotech and Zelluna expand lentiviral vector partnership to advance off-the-shelf TCR-NK therapy for solid tumours

The pair have announced an update to their long-standing manufacturing partnership, advancing lentiviral vector production for Zelluna's lead TCR-NK programme, ZI-MA4-1, targeting the MAGE-A4 tumour antigen, which is planned to enter clinical trials in 2026
Manufacturing

Romaco unveils the KTS 840 at interpack - Powerful tableting technology for triple-layer tablets

Karlsruhe/Germany, 2026-04-28 - At interpack 2026, Romaco Kilian will be presenting the KTS 840 – its new tablet press for triple-layer applications. This robust rotary tablet press was specially designed for use in the nutraceutical and food industries. In addition, Romaco will join with Theegarten-PACTEC to exhibit a high speed line for compressing and packaging bouillon cubes. With the KTP 1X compaction simulator, Romaco will showcase its expertise in research and development
Manufacturing

Ecolab Life Sciences opens bioprocessing applications lab in Korea to support downstream process development across Asia

New facility serves biopharma manufacturers throughout the region with local access to customer purification studies across Ecolab's Purolite Resin portfolio
Subscribe now